Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

icon1
USD 104.15 BN
MARKET SIZE, 2030
icon2
CAGR 10.8%
(2025-2030)
icon3
557
REPORT PAGES
icon4
704
MARKET TABLES

OVERVIEW

biomarkers-advanced-technologies-and-global-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The biomarkers market is projected to reach USD 104.15 billion by 2030 from USD 62.39 billion in 2025 at a CAGR of 10.8% from 2025 to 2030. The market growth is fueled by the increasing use of biomarkers in drug discovery, which helps identify disease mechanisms and enhances the accuracy of clinical trials.

KEY TAKEAWAYS

  • BY REGION
    The North America biomarkers market dominated, with a share of 40.2% in 2024. The large share of North America can be attributed to the presence of key biopharmaceutical research and development facilities and the rising number of drug development projects.
  • BY OFFERING
    By offering, the consumables segment is expected to dominate the market, growing at the highest CAGR of 11.5%. The growth in this segment is driven by the necessity for high-quality products to ensure accurate test results in research and clinical settings.
  • BY TYPE
    By type, the safety biomarkers segment accounted for the largest share of 48.1%. market. The large share of this segment is due to its essential role in ensuring the safety and effectiveness of pharmaceuticals and healthcare interventions.
  • BY RESEARCH AREA
    By research area, the genomics segment is expected to register the highest CAGR of 11.6%. Increasing advancements in genomics technologies for biomarker testing are expected to drive the growth in this segment.
  • COMPETITIVE LANDSCAPE
    F. Hoffmann-La Roche Ltd, Merck KGaA, Abbott, Thermo Fisher Scientific Inc. and QIAGEN were identified as Star players in the biomarkers market, as they have focused on innovation and have broad industry coverage and strong operational & financial strength.

The biomarkers market is projected to grow significantly over the next decade, driven by the increasing use of biomarkers in drug discovery, which helps identify disease mechanisms and enhances the accuracy of clinical trials. Investments in omics technologies, including genomics, proteomics, and transcriptomics, are improving the processes for biomarker identification and validation. Moreover, both governments and private organizations are providing more funding and grants for biomarker research.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The biomarkers market is witnessing a major transformation driven by new technologies, evolving applications, and strategic collaborations. The revenue mix is expected to shift significantly as companies move from conventional models toward multi-omics integration, AI-enabled biomarker discovery, and liquid biopsy innovations. Pharmaceutical and biotechnology companies, hospitals, academic institutions, and other end users are prioritizing assay validation, regulatory compliance, and precision diagnostics. These advancements aim to accelerate disease detection, improve patient stratification, reduce clinical trial failures, and enhance precision medicine outcomes, ultimately driving better healthcare efficiency and early diagnosis worldwide.

biomarkers-advanced-technologies-and-global-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing use of biomarkers in drug discovery & development
  • Growing importance of companion diagnostics
RESTRAINTS
Impact
Level
  • High capital investments and extensive timelines for biomarker development
  • Disease complexity and heterogeneity
OPPORTUNITIES
Impact
Level
  • Growing preference for personalized medicine and precision oncology
  • High growth potential of emerging economies
CHALLENGES
Impact
Level
  • Issues associated with quantification & validation of biomarkers
  • Complexities associated with data set integration

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing use of biomarkers in drug discovery & development

The growing use of biomarkers in drug discovery and development enhances disease understanding, patient selection, and therapeutic efficacy. Their integration accelerates clinical trials, reduces costs, and improves success rates by enabling more targeted, data-driven drug development strategies across pharmaceutical and biotechnology research programs.

Restraint: High capital investments and extensive timelines for biomarker development

Developing reliable biomarkers requires substantial investment, advanced infrastructure, and long validation timelines. High R&D costs, regulatory complexities, and limited funding restrict smaller players, slowing innovation and commercial adoption. These factors collectively hinder the large-scale implementation of biomarkers in clinical and research applications

Opportunity: Growing preference for personalized medicine and precision oncology

The rising focus on personalized medicine and precision oncology offers strong growth prospects for the biomarkers market. Biomarkers are vital for identifying patient-specific traits, predicting drug response, and monitoring therapy effectiveness, driving their adoption in companion diagnostics and targeted treatment development.

Challenge: Issues associated with quantification & validation of biomarkers

Accurate quantification and validation remain key challenges in biomarker research. Variations in assay performance, lack of standardization, and reproducibility issues impede clinical translation and regulatory approval. Addressing these limitations is crucial to ensure data reliability and accelerate biomarker integration into diagnostic and therapeutic applications.

biomarkers-advanced-technologies-and-global-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Collaborated with the COPD Foundation Biomarker Qualification Consortium, developed and validated plasma fibrinogen as a prognostic biomarker for chronic obstructive pulmonary disease (COPD) Enabled selection of high-risk patients, reduced trial size and duration, and improved statistical power and regulatory acceptance for biomarker-driven studies
Applied bioinformatics to identify KRAS pathway biomarkers that rescued a failing oncology clinical trial by defining a responder subgroup Enabled redesign of the trial with biomarker-guided patient selection, demonstrated efficacy in a specific subgroup, and revived a previously non-performing drug candidate

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The biomarkers market ecosystem comprises raw material suppliers (Biosynth, Creative Diagnostics), product manufacturers (Agilent Technologies, Thermo Fisher Scientific), service providers (JSR Corporation, Eurofins), and end users (Novartis,Massachusetts General Hospital). Raw materials like reagents, assay kits, antibodies, and detection enzymes are utilized to develop, validate, and apply biomarkers in disease diagnosis, drug discovery, and clinical research. Product manufacturers ensure standardized assay platforms and analytical instruments, while service providers deliver biomarker validation, testing, and translational research support. End users drive demand for accuracy, clinical relevance, and regulatory compliance, fostering collaboration across the value chain. This integrated ecosystem promotes innovation in precision medicine, early disease detection, and personalized therapeutic development.

biomarkers-advanced-technologies-and-global-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

biomarkers-advanced-technologies-and-global-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Biomarkers Market, By Offering

In 2024, the consumables segment accounted for the largest share of the biomarkers market. The high demand for consumables stems from the necessity for high-quality products to ensure accurate and reliable results in biomarker testing.

Biomarkers Market, By Type

In 2024, the safety biomarkers segment accounted for the largest share of the biomarkers market. The large share of this segment is due to its essential role in ensuring the safety and effectiveness of pharmaceuticals and healthcare interventions.

Biomarkers Market, By Application

In 2024, the clinical diagnostics segment accounted for the largest share of the biomarkers market. The large share of this segment can be attributed to the increasing use of biomarkers for disease diagnosis and the rising incidence of chronic diseases such as cancer, infectious diseases, cardiovascular disorders, and neurological disorders.

REGION

Asia Pacific to be fastest-growing region in global biomarkers market during forecast period

The Asia Pacific biomarkers market is expected to register the highest CAGR during the forecast period, primarily due to the rising incidence of chronic diseases, the rapid expansion of drug discovery & development projects, increasing R&D spending on biopharmaceutical projects, and the growth of the biotechnology industry in emerging economies.

biomarkers-advanced-technologies-and-global-market Region

biomarkers-advanced-technologies-and-global-market: COMPANY EVALUATION MATRIX

F. Hoffmann-La Roche Ltd (Star) leads the biomarkers market with a strong global footprint, leveraging its extensive portfolio of biomarker-based diagnostics, companion diagnostics, and precision medicine platforms integrated across its pharmaceutical and diagnostics divisions. The company’s regulatory expertise, clinical validation capabilities, and strategic collaborations reinforce its leadership in biomarker innovation across oncology, neurology, and infectious diseases. Guardant Health (Emerging Leader) is rapidly strengthening its market position through advanced liquid biopsy and genomic profiling technologies, addressing the growing demand for non-invasive, real-time, and clinically actionable biomarker testing solutions.

biomarkers-advanced-technologies-and-global-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 58.07 Billion
Market Forecast in 2030 (Value) USD 104.15 Billion
Growth Rate CAGR of 10.8% from 2025 to 2030
Years Considered 2023–2030
Base Year 2024
Forecast Period 2025–2030
Units Considered Value (USD Billion)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Offering:
    • Consumables
    • Services
    • Software
  • By Type:
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Validation Biomarkers
  • By Research Area:
    • Genomics
    • Proteomics
    • Metabolomics
    • Other Research Areas
  • By Technology:
    • Immunoassays
    • Next-generation Sequencing
    • Polymerase Chain Reaction
    • Mass Spectrometry
    • Chromatography
    • Other Technologies
  • By Disease Indication:
    • Cancer
    • Infectious Diseases
    • Neurological Diseases
    • Cardiovascular Diseases
    • Other Disease Indications
  • By Application:
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Personalized Medicine
    • Clinical Research
    • Other Applications
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Hospitals & Diagnostic Laboratories
    • Academic & Research Institutes
    • Other End Users
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: biomarkers-advanced-technologies-and-global-market REPORT CONTENT GUIDE

biomarkers-advanced-technologies-and-global-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Rest of Asia Pacific Breakdown Country-level market sizing and growth forecasts (Taiwan, North Korea, New Zealand, Vietnam, the Philippines, Singapore, Malaysia,Thailand, Indonesia, and other Asia Pacific countries) Provides granular country-level insights, enabling clients to prioritize high-growth markets, and tailor portfolio strategies
Company Evaluation
  • Detailed analysis and profiling of top five market players
  • Portfolio assessment of top five companies
 Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions

RECENT DEVELOPMENTS

  • May 2025 : Roche introduced the Elecsys PRO-C3 test, a biomarker-based diagnostic tool, developed with Nordic Bioscience to evaluate liver fibrosis severity in patients with MASLD (metabolic dysfunction-associated steatotic liver disease).
  • April 2025 : Eurofins Scientific acquired SYNLAB's clinical diagnostics operations in Spain, which include genetics and anatomical pathology services. These services complement Eurofins' existing clinical diagnostics capabilities and significantly expand its reach in the Spanish market. The acquisition supports Eurofins' biomarker services by strengthening its access to patient samples, enhancing laboratory throughput, and expanding its capabilities in molecular diagnostics, essential for biomarker discovery, validation, and clinical application.
  • January 2025 : Merck established a multi-year partnership with Opentrons Labworks to automate its biology assay kits using the Opentrons Flex robotic workstation. This collaboration aims to enhance workflows related to protein sample preparation, molecular assays, and cell-based research, which are crucial for biomarker discovery and validation.
  • January 2025 : Thermo Fisher Scientific teamed up with the UK Biobank Pharma Proteomics Project (UKB-PPP) to conduct the world's largest proteomics study focused on biomarkers. Utilizing Thermo Fisher's Olink Explore Platform, this collaboration will analyze more than 5,400 proteins from 600,000 human samples, aiming to accelerate the discovery of protein biomarkers associated with various diseases.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
43
RESEARCH METHODOLOGY
49
EXECUTIVE SUMMARY
62
PREMIUM INSIGHTS
67
MARKET OVERVIEW
This Section Addresses the Market Dynamics and Upcoming Trends Shaping the Biomarkers Market
70
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    MARKET DRIVERS
    - Increasing use of biomarkers in drug discovery & development
    - Growing importance of companion diagnostics
    - Rising prevalence of cancer
    - Development of biomarkers for rare diseases
    - Increasing funds and grants for biomarker research
    - Advancement in omics technologies
    RESTRAINTS
    - High capital investments and extensive timelines for biomarker development
    - Disease complexity and heterogeneity
    OPPORTUNITIES
    - Growing preference for personalized medicine and precision oncology
    - Enhanced collaboration among healthcare providers and key industry players
    - High growth potential of emerging economies
    CHALLENGES
    - Issues associated with quantification & validation of biomarkers
    - Complexities associated with data set integration
    - Technical issues related to sample collection and storage
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 REGULATORY ANALYSIS
    REGULATORY SCENARIO
    - US
    - Europe
    - Asia Pacific
    - Rest of the World
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 TECHNOLOGICAL ANALYSIS
    KEY TECHNOLOGIES
    - Immunoassays
    - Next-generation Sequencing (NGS)
    - Polymerase chain reaction (PCR)
    - In situ hybridization
    - Microarrays
    - Mass Spectrometry
    COMPLEMENTARY TECHNOLOGIES
    - Liquid biopsy
    - CRISPR
    ADJACENT TECHNOLOGIES
    - Artificial intelligence (AI) and machine learning (ML)
    - Sensors (wearable devices)
  • 5.7 PRICING ANALYSIS
    INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022–2024
    INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024
  • 5.8 PATENT ANALYSIS
    METHODOLOGY
    NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2025
  • 5.9 ECOSYSTEM ANALYSIS
  • 5.10 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.11 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BIOMARKERS MARKET: BUYING CRITERIA
  • 5.13 INVESTMENT & FUNDING SCENARIO
  • 5.14 TRADE DATA ANALYSIS
    IMPORT SCENARIO: HS CODE 382200, 2020–2024
    EXPORT SCENARIO: HS CODE 382200, 2020–2024
  • 5.15 IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET
    INTRODUCTION
    USE CASES
    FUTURE OF AI IN BIOMARKER ECOSYSTEM
  • 5.16 IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRIES/REGIONS
    - US
    - Europe
    - Asia Pacific
    IMPACT ON END-USE INDUSTRIES
    - Pharmaceutical & biotech companies
    - Hospitals & diagnostic laboratories
    - Contract research organizations
BIOMARKERS MARKET, BY OFFERING
Detailed Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market, By Offerings– Value USD Million
123
  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    ASSAY KITS
    - Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth
    REAGENTS & CHEMICALS
    - Recurrent usage of reagents & chemicals in drug discovery and development to support demand
    OTHER CONSUMABLES
  • 6.3 SERVICES
    GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
  • 6.4 SOFTWARE
    INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH
BIOMARKERS MARKET, BY TYPE
Detailed Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market, By Type– Value USD Million
147
  • 7.1 INTRODUCTION
  • 7.2 SAFETY BIOMARKERS
    WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH
  • 7.3 EFFICACY BIOMARKERS
    PREDICTIVE BIOMARKERS
    - Rising applications of biomarkers in personalized medicine to drive market
    SURROGATE BIOMARKERS
    - Ability to serve as reliable indicator in place of clinical endpoints to support market growth
    PHARMACODYNAMIC BIOMARKERS
    - Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market
    PROGNOSTIC BIOMARKERS
    - Increasing number of clinical trials to support growth of prognostic biomarkers
  • 7.4 VALIDATION BIOMARKERS
    RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH
BIOMARKERS MARKET, BY RESEARCH AREA
Detailed Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market, By Research Area– Value USD Million
174
  • 8.1 INTRODUCTION
  • 8.2 GENOMICS
    ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
  • 8.3 PROTEOMICS
    GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
  • 8.4 METABOLOMICS
    RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
  • 8.5 OTHER RESEARCH AREAS
BIOMARKERS MARKET, BY TECHNOLOGY
Detailed Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market, By Technology– Value USD Million
190
  • 9.1 INTRODUCTION
  • 9.2 IMMUNOASSAYS
    ELISA
    - Extensive application of ELISA assays in clinical laboratories to support growth
    PROTEIN MICROARRAYS
    - Quick and cost-effective nature of technology to support growth
    WESTERN BLOT
    - Increasing investments in proteomics research to drive market
  • 9.3 NEXT-GENERATION SEQUENCING (NGS)
    TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
  • 9.4 POLYMERASE CHAIN REACTION (PCR)
    RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
  • 9.5 MASS SPECTROMETRY
    INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH
  • 9.6 CHROMATOGRAPHY
    GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
  • 9.7 OTHER TECHNOLOGIES
BIOMARKERS MARKET, BY DISEASE INDICATION
Detailed Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market, By Disease Indication– Value USD Million
225
  • 10.1 INTRODUCTION
  • 10.2 CANCER
    INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
  • 10.3 INFECTIOUS DISEASES
    INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND
  • 10.4 IMMUNOLOGICAL DISORDERS
    RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET
  • 10.5 NEUROLOGICAL DISORDERS
    WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH
  • 10.6 CARDIOVASCULAR DISORDERS
    GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
  • 10.7 OTHER DISEASE INDICATIONS
BIOMARKERS MARKET, BY APPLICATION
Detailed Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market, By Application– Value USD Million
251
  • 11.1 INTRODUCTION
  • 11.2 CLINICAL DIAGNOSTICS
    GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
  • 11.3 DRUG DISCOVERY & DEVELOPMENT
    INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
  • 11.4 PERSONALIZED MEDICINE
    GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
  • 11.5 CLINICAL RESEARCH
    GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
  • 11.6 OTHER APPLICATIONS
BIOMARKERS MARKET, BY END USER
Detailed Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market, By End User– Value USD Million
272
  • 12.1 INTRODUCTION
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES
    GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
  • 12.3 HOSPITALS & DIAGNOSTIC LABORATORIES
    VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH
  • 12.4 ACADEMIC & RESEARCH INSTITUTES
    INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
  • 12.5 OTHER END USERS
BIOMARKERS MARKET, BY REGION
Detailed Region & Country-level Analysis of Market Size (2022-2030) & Forecast To 2030 for Biomarkers Market– Value USD Million
289
  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK OF NORTH AMERICA
    US
    - Rising focus on biopharma research to support growth
    CANADA
    - Increasing incidence of cancer to drive biomarkers market growth
  • 13.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Growth in biopharmaceutical R&D activities to propel growth
    UK
    - Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
    FRANCE
    - Increasing government investment for proteomics & genomics research to drive growth
    ITALY
    - Increasing developments in life science research to fuel growth
    SPAIN
    - R&D initiatives for personalized medicine to support market growth
    REST OF EUROPE
  • 13.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Rising incidence of CVD to propel market
    JAPAN
    - Strong regulatory guidelines for drug discovery & development to support market growth
    INDIA
    - Favorable scenario for FDI and increasing number of clinical trials to propel market
    SOUTH KOREA
    - Increasing innovations in NGS technologies to support market growth
    AUSTRALIA
    - Increasing demand for diagnostic solutions to propel market
    REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Increased government investments in pharmaceutical R&D to drive market
    MEXICO
    - Rising demand for chronic disease treatment to support market growth
    REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    SAUDI ARABIA
    - Growing healthcare expenditure to boost market growth
    UAE
    - Increasing collaborative efforts for pharmaceutical R&D to drive growth
    REST OF GCC COUNTRIES
    - Other GCC countries include Bahrain, Kuwait, Oman, and Qatar.
    REST OF MIDDLE EAST
    - The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq.
  • 13.7 AFRICA
    INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
Market Share Analysis (%), Revenue Analysis (USD Million) & Competitive Positioning Matrix for Biomarkers Market
432
  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET
  • 14.3 REVENUE ANALYSIS, 2022–2024
  • 14.4 MARKET SHARE ANALYSIS, 2024
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Offering footprint
    - Technology footprint
    - Application footprint
  • 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 14.7 COMPANY VALUATION & FINANCIAL METRICS
    VALUATION OF KEY PLAYERS
    FINANCIAL METRICS OF KEY PLAYERS
  • 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
    BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS
  • 14.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
In-Depth Profiles of Key Players and SMEs/Start-ups Operating in Biomarkers Market with Business Overview, Financials, Product/Service Portfolio, Recent Developments
462
  • 15.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    MERCK KGAA
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products & services offered
    - Recent developments
    QIAGEN
    - Business overview
    - Products & services offered
    - Recent developments
    ABBOTT
    - Business overview
    - Products & services offered
    - Recent developments
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    REVVITY INC.
    - Business overview
    - Products & services offered
    CHARLES RIVER LABORATORIES
    - Business overview
    - Products & services offered
    - Recent developments
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    EUROFINS SCIENTIFIC
    - Business overview
    - Products & services offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products & services offered
    - Recent developments
    ILLUMINA, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    JSR CORPORATION
    - Business overview
    - Products & services offered
    - Recent developments
    GUARDANT HEALTH
    - Business overview
    - Products & services offered
    - Recent developments
    LABCORP
    - Business overview
    - Products & services offered
    - Recent developments
    QUANTERIX
    - Business overview
    - Products & services offered
    - Recent developments
    MESO SCALE DIAGNOSTICS, LLC
    - Business overview
    - Products & services offered
  • 15.2 OTHER PLAYERS
    CELERION
    STANDARD BIOTOOLS
    SEBIA
    BIOAGILYTIX LABS
    STRESSMARQ BIOSCIENCES INC.
    NORTHEAST BIOANALYTICAL LABORATORIES LLC
    SIGNOSIS
    SERIMMUNE
    THERAINDX LIFESCIENCES PVT. LTD.
    SYNEXA LIFE SCIENCES BV
    DIATECH PHARMACOGENETICS
    SINGULEX, INC.
    R-BIOPHARM AG
APPENDIX
549
  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 BIOMARKERS MARKET: IMPACT ANALYSIS
  • TABLE 2 CANCER INCIDENCE, BY REGION (2040)
  • TABLE 3 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, 2022−2024
  • TABLE 4 TIMEFRAME FOR BIOMARKER DEVELOPMENT
  • TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022–2024 (USD)
  • TABLE 10 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024 (USD)
  • TABLE 11 NUMBER OF PATENTS FILED IN BIOMARKERS MARKET, 2014–2025
  • TABLE 12 DETAILED ANALYSIS OF KEY PATENTS IN BIOMARKERS MARKET, 2024–2025
  • TABLE 13 BIOMARKERS MARKET: ECOSYSTEM
  • TABLE 14 BIOMARKERS MARKET: LIST OF CONFERENCES & EVENTS, 2025–2026
  • TABLE 15 BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKER-BASED OFFERINGS
  • TABLE 17 BUYING CRITERIA FOR BIOMARKER PRODUCTS, BY END USER
  • TABLE 18 CANCER BIOMARKER FUNDING BY VARIOUS INSTITUTES/CENTERS IN US, 2021–2024
  • TABLE 19 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2020–2024 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2020–2024 (USD THOUSAND)
  • TABLE 21 TABLE 1: US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 22 BIOMARKER PRODUCT-RELATED TARIFF REVISIONS
  • TABLE 23 IMPACT ON END-USE APPLICATIONS OF BIOMARKER PRODUCTS
  • TABLE 24 BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 25 BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 26 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 27 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 30 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 31 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 33 BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 35 EUROPE: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 39 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 40 BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 41 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 42 EUROPE: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 44 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 45 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 46 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 47 OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 48 NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 49 EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 52 MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 53 GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 BIOMARKER SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 55 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 56 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 58 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 59 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 60 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY,2023–2030 (USD MILLION)
  • TABLE 61 BIOMARKER SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 62 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 65 LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 66 MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 67 GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 68 BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 69 SAFETY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 71 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY,2023–2030 (USD MILLION)
  • TABLE 73 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 74 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 75 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 76 EFFICACY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 77 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 78 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 81 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 82 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 84 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 85 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 86 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 87 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 88 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 89 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 90 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 91 SURROGATE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 93 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 96 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 97 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 98 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION,2023–2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 100 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 102 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 103 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 104 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 105 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 106 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 107 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 109 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 110 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 111 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 VALIDATION BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 113 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 114 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 116 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 117 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 118 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 119 BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 120 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 122 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 124 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 125 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 126 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 127 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 128 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 129 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 131 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 132 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 133 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 134 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 135 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 136 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 138 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 139 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 140 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 141 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 143 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 145 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 146 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 147 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 148 BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 149 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 150 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 151 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 153 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 154 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 155 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 156 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 157 BIOMARKERS MARKET FOR ELISA, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 158 NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 159 EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 161 LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 162 MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 163 GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 164 BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 165 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 166 EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 168 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS,BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 170 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 171 BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 172 NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 173 EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 175 LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 176 MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 177 GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 178 BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 179 NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 180 EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 182 LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 183 MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 184 GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2023–2030 (USD MILLION)
  • TABLE 185 BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 186 NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 187 EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 189 LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 190 MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 191 GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 192 BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 193 NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 194 EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 196 LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 197 MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY,BY REGION, 2023–2030 (USD MILLION)
  • TABLE 198 GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 199 BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 200 NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 201 EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY,BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 203 LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 204 MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 205 GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 206 BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 207 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 208 EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 210 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 211 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES,BY REGION, 2023–2030 (USD MILLION)
  • TABLE 212 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 213 BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 214 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE
  • TABLE 215 BIOMARKERS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 216 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 217 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 219 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 220 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 221 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 222 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 223 NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 224 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 226 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 227 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 228 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 229 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
  • TABLE 230 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 231 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 232 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 234 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 235 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 236 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 237 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 238 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 239 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 241 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 242 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 243 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 244 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
  • TABLE 245 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 246 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 247 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 248 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 249 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 250 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 251 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS,BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 252 BIOMARKERS FOR RENAL DISORDERS
  • TABLE 253 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 254 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 255 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 256 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 257 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 258 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 260 BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 261 BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 262 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 263 EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 264 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 265 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 266 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 267 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 268 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 269 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 270 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 271 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 272 LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 273 MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 274 GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 275 LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS
  • TABLE 276 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 277 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 278 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 279 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 280 LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 281 MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 282 GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 283 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION
  • TABLE 284 BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 285 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 286 EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 287 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 288 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 289 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 291 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 292 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 293 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 295 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 296 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 297 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 298 BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 299 PHARMA & BIOTECH SECTOR: RECENT DEVELOPMENTS
  • TABLE 300 BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 301 NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 302 EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 303 ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 304 LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 305 MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 306 GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 307 BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 308 NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 309 EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 310 ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 311 LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 312 MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 313 GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 314 BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 315 NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 316 EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 318 LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 319 MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 320 GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 321 BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 322 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 323 EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 324 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 325 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 326 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 327 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 328 BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 329 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 330 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 331 NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 332 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 333 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 334 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 335 NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 336 NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 337 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 338 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 339 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 340 NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 341 US: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 342 US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 343 US: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 344 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 345 US: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 346 US: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 347 US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 348 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 349 US: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 350 US: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 351 CANADA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 352 CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 353 CANADA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 354 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 355 CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 356 CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 357 CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 358 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 359 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 360 CANADA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 361 EUROPE: KEY MACROINDICATORS
  • TABLE 362 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 363 EUROPE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 364 EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 365 EUROPE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 366 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 367 EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 368 EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 369 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 370 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 371 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 372 EUROPE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 373 GERMANY: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 374 GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 375 GERMANY: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 376 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 377 GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 378 GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 379 GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE,2023–2030 (USD MILLION)
  • TABLE 380 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 381 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 382 GERMANY: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 383 UK: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 384 UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 385 UK: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 386 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 387 UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 388 UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 389 UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 390 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 391 UK: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 392 UK: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 393 FRANCE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 394 FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 395 FRANCE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 396 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 397 FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 398 FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 399 FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 400 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 401 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 402 FRANCE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 403 ITALY: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 404 ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 405 ITALY: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 406 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 407 ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 408 ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 409 ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 410 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 411 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 412 ITALY: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 413 SPAIN: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 414 SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 415 SPAIN: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 416 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 417 SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 418 SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 419 SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 420 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 421 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 422 SPAIN: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 423 REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 424 REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 425 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 426 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 427 REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 428 REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 429 REST OF EUROPE: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 430 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 431 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 432 REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 433 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 434 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 435 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 436 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 437 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 438 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 439 ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 440 ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 441 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 442 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 443 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 444 ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 445 CHINA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 446 CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 447 CHINA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 448 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 449 CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 450 CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 451 CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 452 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 453 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 454 CHINA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 455 JAPAN: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 456 JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 457 JAPAN: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 458 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 459 JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 460 JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 461 JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 462 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION,2023–2030 (USD MILLION)
  • TABLE 463 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 464 JAPAN: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 465 INDIA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 466 INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 467 INDIA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 468 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 469 INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 470 INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 471 INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 472 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 473 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 474 INDIA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 475 SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 476 SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 477 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 478 SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 479 SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 480 SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 481 SOUTH KOREA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 482 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 483 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 484 SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 485 AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 486 AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 487 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 488 AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 489 AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 490 AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 491 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 492 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 493 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 494 AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 495 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 496 REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 497 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 498 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 499 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 500 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 501 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 502 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 503 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 504 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 505 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 506 LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 507 LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 508 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 509 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 510 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 511 LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 512 LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 513 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 514 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 515 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 516 LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 517 BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 518 BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 519 BRAZIL: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 520 BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 521 BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 522 BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 523 BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 524 BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 525 BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 526 BRAZIL: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 527 MEXICO: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 528 MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 529 MEXICO: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 530 MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 531 MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 532 MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 533 MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 534 MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 535 MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 536 MEXICO: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 537 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 538 REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 539 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 540 REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 541 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 542 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 543 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 544 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 545 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 546 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 547 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 548 MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 549 MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 550 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 551 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 552 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE,2023–2030 (USD MILLION)
  • TABLE 553 MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 554 MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 555 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 556 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 557 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 558 MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 559 GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 560 GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 561 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 562 GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 563 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 564 GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 565 GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 566 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 567 GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 568 GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 569 GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 570 SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 571 SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 572 SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 573 SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 574 SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 575 SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 576 SAUDI ARABIA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 577 SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 578 SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 579 SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 580 UAE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 581 UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 582 UAE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 583 UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 584 UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 585 UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 586 UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 587 UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 588 UAE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 589 UAE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 590 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 591 REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 592 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 593 REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 594 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 595 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 596 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 597 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 598 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 599 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 600 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 601 REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 602 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 603 REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 604 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 605 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 606 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 607 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 608 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 609 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 610 AFRICA: KEY MACROINDICATORS
  • TABLE 611 AFRICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)
  • TABLE 612 AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 613 AFRICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 614 AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 615 AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)
  • TABLE 616 AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
  • TABLE 617 AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 618 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)
  • TABLE 619 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 620 AFRICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 621 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET
  • TABLE 622 BIOMARKERS MARKET: DEGREE OF COMPETITION
  • TABLE 623 BIOMARKERS MARKET: REGION FOOTPRINT
  • TABLE 624 BIOMARKERS MARKET: OFFERING FOOTPRINT
  • TABLE 625 BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 626 BIOMARKERS MARKET: APPLICATION FOOTPRINT
  • TABLE 627 BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 628 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES PLAYERS
  • TABLE 629 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 630 BIOMARKERS MARKET: DEALS, JANUARY 2022–MAY 2025
  • TABLE 631 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2022–MAY 2025
  • TABLE 632 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
  • TABLE 633 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 634 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025
  • TABLE 635 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–APRIL 2025
  • TABLE 636 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–APRIL 2025
  • TABLE 637 MERCK KGAA: BUSINESS OVERVIEW
  • TABLE 638 MERCK KGAA OFFERINGS: PRODUCTS & SERVICES OFFERED
  • TABLE 639 MERCK KGAA: DEALS, JANUARY 2022–APRIL 2025
  • TABLE 640 MERCK KGAA: EXPANSIONS, JANUARY 2022–APRIL 2025
  • TABLE 641 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
  • TABLE 642 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
  • TABLE 643 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025
  • TABLE 644 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–APRIL 2025
  • TABLE 645 QIAGEN: BUSINESS OVERVIEW
  • TABLE 646 QIAGEN: PRODUCTS & SERVICES OFFERED
  • TABLE 647 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025
  • TABLE 648 QIAGEN: DEALS, JANUARY 2022–APRIL 2025
  • TABLE 649 QIAGEN: EXPANSIONS, JANUARY 2022–APRIL 2025
  • TABLE 650 ABBOTT: BUSINESS OVERVIEW
  • TABLE 651 ABBOTT: PRODUCTS & SERVICES OFFERED
  • TABLE 652 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022—APRIL 2025
  • TABLE 653 ABBOTT: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 654 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
  • TABLE 655 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 656 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022—APRIL 2025
  • TABLE 657 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 658 REVVITY INC.: BUSINESS OVERVIEW
  • TABLE 659 REVVITY INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 660 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
  • TABLE 661 CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED
  • TABLE 662 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 663 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
  • TABLE 664 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 665 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022—APRIL 2025
  • TABLE 666 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 667 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
  • TABLE 668 EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED
  • TABLE 669 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 670 BIOMÉRIEUX: BUSINESS OVERVIEW
  • TABLE 671 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED
  • TABLE 672 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025
  • TABLE 673 BIOMÉRIEUX: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 674 ILLUMINA, INC.: BUSINESS OVERVIEW
  • TABLE 675 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 676 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025
  • TABLE 677 ILLUMINA, INC.: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 678 JSR CORPORATION: BUSINESS OVERVIEW
  • TABLE 679 JSR CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 680 JSR CORPORATION: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 681 GUARDANT HEALTH: BUSINESS OVERVIEW
  • TABLE 682 GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED
  • TABLE 683 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025
  • TABLE 684 GUARDANT HEALTH: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 685 LABCORP: BUSINESS OVERVIEW
  • TABLE 686 LABCORP: PRODUCTS & SERVICES OFFERED
  • TABLE 687 LABCORP: PRODUCT LAUNCHES, JANUARY 2022—APRIL 2025
  • TABLE 688 QUANTERIX: BUSINESS OVERVIEW
  • TABLE 689 QUANTERIX: PRODUCTS & SERVICES OFFERED
  • TABLE 690 QUANTERIX: PRODUCT LAUNCHES, JANUARY 2022—APRIL 2025
  • TABLE 691 QUANTERIX: DEALS, JANUARY 2022—APRIL 2025
  • TABLE 692 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
  • TABLE 693 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED
  • TABLE 694 CELERION: COMPANY OVERVIEW
  • TABLE 695 STANDARD BIOTOOLS: COMPANY OVERVIEW
  • TABLE 696 SEBIA: COMPANY OVERVIEW
  • TABLE 697 BIOAGILYTIX LABS: COMPANY OVERVIEW
  • TABLE 698 STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW
  • TABLE 699 NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW
  • TABLE 700 SIGNOSIS: BUSINESS OVERVIEW
  • TABLE 701 SERIMMUNE: BUSINESS OVERVIEW
  • TABLE 702 THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW
  • TABLE 703 SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW
  • TABLE 704 DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW
  • TABLE 705 SINGULEX, INC.: BUSINESS OVERVIEW
  • TABLE 706 R-BIOPHARM AG: BUSINESS OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BIOMARKERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 3 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024
  • FIGURE 5 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2024)
  • FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 8 BIOMARKERS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
  • FIGURE 9 BIOMARKERS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 BIOMARKERS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 BIOMARKERS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 BIOMARKERS MARKET, BY RESEARCH AREA, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 BIOMARKERS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 BIOMARKERS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 GEOGRAPHIC ANALYSIS: BIOMARKERS MARKET
  • FIGURE 17 GROWING PIPELINE OF PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
  • FIGURE 18 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF BIOMARKERS MARKET IN ASIA PACIFIC IN 2024
  • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL BIOMARKERS MARKET DURING FORECAST PERIOD
  • FIGURE 21 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 23 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 AVERAGE SELLING PRICE OF ASSAY KITS, BY KEY PLAYER, 2022–2024 (USD)
  • FIGURE 25 PATENT ANALYSIS OF BIOMARKERS MARKET, JANUARY 2014–MAY 2025
  • FIGURE 26 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKER-BASED OFFERINGS
  • FIGURE 29 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 30 IMPACT OF AI ON BIOMARKER ECOSYSTEM
  • FIGURE 31 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
  • FIGURE 32 ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2022–2024 (USD MILLION)
  • FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2024
  • FIGURE 35 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 36 BIOMARKERS MARKET: COMPANY FOOTPRINT
  • FIGURE 37 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 38 EV/EBITDA OF KEY VENDORS
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 40 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS
  • FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2024)
  • FIGURE 45 ABBOTT: COMPANY SNAPSHOT (2024)
  • FIGURE 46 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 REVVITY INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
  • FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
  • FIGURE 51 BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
  • FIGURE 52 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 JSR CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 54 GUARDANT HEALTH: COMPANY SNAPSHOT (2024)
  • FIGURE 55 LABCORP: COMPANY SNAPSHOT (2024)
  • FIGURE 56 QUANTERIX: COMPANY SNAPSHOT (2024)

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biomarkers market. The secondary sources used for this study include American Society of Clinical Oncology (ASCO), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organization (CDSCO), Center for Disease Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), Chinese Medical Journal, Clinicaltrials.gov.in, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), Organization for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, World Health Organization (WHO), Corporate and Regulatory Filings, Annual Reports, Sec Filings, Investor Presentations, and Financial Statements; Business Magazines & Research Journals; Press Releases, MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global biomarkers market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & and biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Biomarkers Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the biomarkers market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the biomarkers market business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach

  • After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Biomarkers Market

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Market Definition

A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes. The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery and development, personalized medicine, and clinical research. It also studies the adoption of biomarkers across key research areas, such as oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type of biomarkers, including safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarker landscape.

Stakeholders

  • Academic & Research Institutes
  • Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
  • Contract Research Organizations (CROs)
  • Biomarkers Service & Software Providers
  • Diagnostics Companies
  • Market Research and Consulting Firms
  • Pharmaceutical and Biotechnology Companies
  • Regulatory Agencies
  • Venture Capitalists
  • Forensics Labs
  • Government organizations
  • Private research firms
  • Contract development and manufacturing organizations (CDMOs)
  • Hospitals and Diagnostic Laboratories

Report Objectives

  • To define, describe, and forecast the global biomarkers market based on offering, type, research area, technology, disease indication, application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments in six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the global biomarkers market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
  • To benchmark players in the biomarkers market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share

 

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Biomarkers Market

Patrick

Mar, 2022

Looking forward to gain more insights on the global Biomarkers Market.

Raymond

Mar, 2022

What are the growth opportunities in Biomarkers Market?.

Jack

Mar, 2022

Can you enlighten us on the end users in Biomarkers Market?.

DMCA.com Protection Status